"Advanced Therapy Showcase in Tokyo#2(ATST#2)" (January 28, 2022)

  • twitter
  • Facebook
  • LINE

As a part of its commitment to facilitate advancement of life sciences and relating industries, the Life Science Innovation Network Japan (LINK-J) launched the series of international partnering event "Advanced Therapy Showcase in Tokyo" (ATST) last year to expedite implementation of novel technologies, innovations, and discoveries by matching seeds and needs. The second edition (ATST#2) was organized in January, 2022.



Opening Remarks

LINK-J (Japan)
The chairperson of the board, Dr. Okano gave a welcome speech.


Alliance for Regenerative Medicine (ARM) (USA)
Elucidated state of the regenerative medicine industry in 2022 from the industry point of view.

4Bio Capital (UK)
Elucidated advanced therapies landscape at the beginning of 2022 from the investor's point of view.

Live-streaming company presentation

Inteligex, Inc. (Canada)
Spoke about their proprietary bioengineered stem cells to repair and regenerate the injured spinal cord.

EpiBone, Inc. (USA)
Explained about their own stem-cell-based bone and cartilage regeneration.

Progenicyte Japan Co., Ltd. (USA)
Elucidated their unique exosomal delivery of DNA-based nucleic acid therapeutics to eliminate cancer stem cells and SARS-CoV2.

DiscGenics, Inc. (USA)
Spoke about their revolutionary regenerative cell-based therapies for patients with degenerative diseases of the spine.

RepliCel Life Sciences, Inc. (Canada)
Explained about their development and commercialization in Japan of cell-based therapies for regeneration of collagen-depleted tissue.

NeuroSyntek Modeling and Manufacturing, Inc. (USA)
Introduced their "CellOptimiser" and "CellDiagnostic" - high-throughput cell processing platforms for cancer diagnostic and therapy.

Cellatoz Therapeutics, Inc. (ROK)
Explained about their innovative cell therapies highlighting on Neuronal Regeneration Promoting Cells (NRPCs) and Musculo-Skeletal Stem Cells (MSSCs).

HaplnScience, Inc. (ROK)
Spoke about an endogenous link protein, rhHAPLN1, an innovative therapy for tissue restoration as an ECM modulator.

Helixmith Co., Ltd. (ROK) *
Explained about their gene therapy approach toward regenerative therapeutics for neuropathy, neuromuscular, and neuroischemic diseases.

PuREC Co., Ltd. (Japan)
Elucidated on their bone regeneration program with novel cell therapy with their extremely purified stem cell, "REC."

Jiksak Bioengineering, Inc. (Japan)
Explained about application of iPSC-derived proprietary Nerve Organoid™ axonal tissue to peripheral nerve repair.

Celaid Therapeutics Inc. (Japan)
Spoke about their development of HSC-based cell therapy products with their unique cell expansion technology.

CellFiber Co., Ltd. (Japan)
Explaind about their proprietary RAMEN cell culture system utilizing unique cell-encapsulated alginate hollow gel tube.

Oncolys BioPharma Inc. (Japan)
Spoke about their cancer virotherapy program and their lead candidate, Telomelysin (OBP-301), a gene-modified oncolytic adenovirus.

GenScript ProBio (Japan)
Explained about their CDMO capabilities for cell and gene therapy products.

Terumo BCT Japan, Inc. (Japan) *
Introduced their hollow fiber based automated cell expansion system, Quantum.

GenomeFrontier Therapeutics, Inc. (Taiwan)
Introduced their gene therapy aiding technologies, virus-free piggyBac transposon system pBac, electroporation kits Quantum Nufect, CAR-T cell expansion supplement iCellar, etc.

Stempeutics Research Pvt. Ltd. (India)
Explained about their allogeneic mesenchymal stromal cell product Stempeucel® for critical limb ischemia management.

PDC*Line Pharma SA (Belgium) *
Explained about their new class of cancer vaccine based on an off-the-shelf antigen presenting plasmacytoid dendritic cells (PDC).

Defymed SAS (France)
Introduced their immune-protective cell macro-encapsulation device MailPan® meant to solve unmet medical needs of chronic diseases.

Eligo Biosicience SAS (France)
Elucidated on their precision gene editing of the microbiome for durable removal of bacterial drivers of diseases.

TreeFrog Therapeutics SAS (France) *
Expounded about their scalable, high quality, and transplantation efficient proprietary alginate micro droplet encapsulation cell expansion system for iPSC-derived cell therapies, C-Stem technology, which is.

Amniotics AB (Sweden)
Spoke about their development programs based on amniotic fluid derived mesenchymal stem cells (MSC).

Salipro Biotech AB (Sweden) *
Explained about their proprietary nano-membrane technology (Salipro®) as an effective drug discovery aid through stabilizing targets at membrane.

Touchlight DNA Services Ltd. (UK)
Introduced their proprietary enzymatic and antibiotic-free DNA vector called doggybone DNA (dbDNA™) aiming at genetic medicine revolution.

The event was attended by 273 participants from pharmaceutical, biotech, and other regenerative medicine-related companies, organizations, and institutions in Japan. For a list of participating companies, please click here.
Thank you very much for your participation.